F.W. Birke

406 total citations
15 papers, 343 citations indexed

About

F.W. Birke is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, F.W. Birke has authored 15 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Cellular and Molecular Neuroscience and 4 papers in Oncology. Recurrent topics in F.W. Birke's work include Neuroscience and Neuropharmacology Research (2 papers), Chemokine receptors and signaling (2 papers) and Epilepsy research and treatment (2 papers). F.W. Birke is often cited by papers focused on Neuroscience and Neuropharmacology Research (2 papers), Chemokine receptors and signaling (2 papers) and Epilepsy research and treatment (2 papers). F.W. Birke collaborates with scholars based in Germany, United States and Austria. F.W. Birke's co-authors include Karl Walter Bock, G. Speck, H.M. Jennewein, Christopher J. Meade, Araceli Encabo, Christoph Romanin, W. R. Kukovetz, Klaus Groschner, H. Heuer and K. H. Weber and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

F.W. Birke

15 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F.W. Birke Germany	9	156	76	52	44	43	15	343
David M. Guido United States	12	180 1.2×	77 1.0×	40 0.8×	23 0.5×	32 0.7×	14	456
Alberto Salis Sweden	5	197 1.3×	40 0.5×	25 0.5×	27 0.6×	38 0.9×	5	403
Silvi Luell United States	15	265 1.7×	99 1.3×	55 1.1×	52 1.2×	24 0.6×	21	590
B. Braceland Canada	9	283 1.8×	55 0.7×	78 1.5×	33 0.8×	32 0.7×	11	538
Paul Sargeant United Kingdom	9	287 1.8×	82 1.1×	19 0.4×	61 1.4×	28 0.7×	9	525
Susumu Tsujimoto Japan	14	261 1.7×	95 1.3×	50 1.0×	28 0.6×	13 0.3×	36	502
Viviane Bertrand France	13	136 0.9×	71 0.9×	50 1.0×	134 3.0×	25 0.6×	19	523
Pushkaraj J. Lad United States	12	240 1.5×	105 1.4×	23 0.4×	27 0.6×	22 0.5×	23	440
F. S. TJOENG United States	9	157 1.0×	179 2.4×	31 0.6×	32 0.7×	14 0.3×	15	468
C. Hariton France	12	191 1.2×	44 0.6×	76 1.5×	43 1.0×	9 0.2×	24	516

Countries citing papers authored by F.W. Birke

Since Specialization

Citations

This map shows the geographic impact of F.W. Birke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F.W. Birke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F.W. Birke more than expected).

Fields of papers citing papers by F.W. Birke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F.W. Birke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F.W. Birke. The network helps show where F.W. Birke may publish in the future.

Co-authorship network of co-authors of F.W. Birke

This figure shows the co-authorship network connecting the top 25 collaborators of F.W. Birke. A scholar is included among the top collaborators of F.W. Birke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F.W. Birke. F.W. Birke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Vedani, Angelo, et al.. (2005). Novel Ligands for the Chemokine Receptor-3 (CCR3): A Receptor-Modeling Study Based on 5D-QSAR. Journal of Medicinal Chemistry. 48(5). 1515–1527. 22 indexed citations

Birke, F.W., et al.. (2004). Pyrrolidinohydroquinazolines––a novel class of CCR3 modulators. Bioorganic & Medicinal Chemistry Letters. 15(3). 669–673. 30 indexed citations

Nagaev, I. Yu., et al.. (2003). Preparation of tritium‐labelled BIIL 260 of high specific radioactivity. Journal of Labelled Compounds and Radiopharmaceuticals. 46(3). 221–230. 4 indexed citations

Birke, F.W., et al.. (2001). In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4 Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 297(1). 458–466. 65 indexed citations

Ensinger, Helmut A., et al.. (1997). WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease. Drug Development Research. 40(2). 144–157. 12 indexed citations

Encabo, Araceli, Christoph Romanin, F.W. Birke, W. R. Kukovetz, & Klaus Groschner. (1996). Inhibition of a store‐operated Ca²⁺ entry pathway in human endothelial cells by the isoquinoline derivative LOE 908. British Journal of Pharmacology. 119(4). 702–706. 53 indexed citations

Birke, F.W., et al.. (1994). Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.. PubMed. 9(3). 205–15. 20 indexed citations

Goetzl, Edward J., Richard Shames, H. J. Yang, et al.. (1994). Inhibition of human HL-60 cell responses to chemotactic factors by antisense messenger RNA depletion of G proteins.. Journal of Biological Chemistry. 269(2). 809–812. 24 indexed citations

Birke, F.W., et al.. (1992). Hetrazepine PAF antagonists.. PubMed. 5(2). 177–82. 8 indexed citations

10.

Brecht, H. M., et al.. (1991). Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.. PubMed. 41(1). 51–9. 13 indexed citations

11.

Birke, F.W. & Helmut A. Ensinger. (1991). Inhibition by the PAF antagonist WEB 2086 of PAF induced inositol‐1,4,5‐trisphosphate production in human platelets. Lipids. 26(12Part1). 1050–1053. 1 indexed citations

12.

Heuer, H., F.W. Birke, J. Casals‐Stenzel, & K. H. Weber. (1988). Inhibition of the binding and aggregation to PAF in vitro in comparison with PAF-antagonism in vivo: An investigation using different types of PAF-antagonists. Prostaglandins. 35(5). 838–838. 7 indexed citations

13.

Heuer, H., et al.. (1988). Biological characterization of the enantiomeric hetrazepines of the paf-antagonist web 2170. Prostaglandins. 35(5). 847–847. 8 indexed citations

14.

Weber, K. H., et al.. (1988). Interactions of hetrazepines with the central benzodiazepine receptor and the PAF receptor. Prostaglandins. 35(5). 847–847. 7 indexed citations

15.

Bock, Karl Walter, et al.. (1976). Metabolism of naphthalene to naphthalene dihydrodiol glucuronide in isolated hepatocytes and in liver microsomes. Biochemical Pharmacology. 25(21). 2351–2356. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact